Trilogy Capital Inc. Humacyte, Inc. Transaction History
Trilogy Capital Inc.
- $1.89 Billion
- Q4 2024
A detailed history of Trilogy Capital Inc. transactions in Humacyte, Inc. stock. As of the latest transaction made, Trilogy Capital Inc. holds 83,500 shares of HUMA stock, worth $385,770. This represents 0.02% of its overall portfolio holdings.
Number of Shares
83,500Holding current value
$385,770% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding HUMA
# of Institutions
153Shares Held
35.4MCall Options Held
279KPut Options Held
607K-
Black Rock Inc. New York, NY7.14MShares$33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$23.4 Million0.0% of portfolio
-
State Street Corp Boston, MA4.76MShares$22 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$9.43 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$5.86 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $476M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...